Ascendis Pharma A/S Reports First Quarter 2017 Financial Results
- Phase 3 Program Advances for TransCon Growth Hormone and Two More Rare Disease Product Candidates Approach Clinic - - Co... Read More
Ascendis Pharma A/S Announces First Quarter 2017 Financial Results Conference Call on May 23
COPENHAGEN, Denmark, May 11, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utiliz... Read More